Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Astragaloside A (Astramembrannin I) 是从黄芪中分离得到的初级纯皂苷,已广泛用于心血管疾病的治疗。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 225 | 现货 | ||
2 mg | ¥ 313 | 现货 | ||
5 mg | ¥ 563 | 现货 | ||
10 mg | ¥ 686 | 现货 | ||
25 mg | ¥ 990 | 现货 | ||
50 mg | ¥ 1,370 | 现货 | ||
100 mg | ¥ 2,470 | 现货 | ||
200 mg | ¥ 3,680 | 现货 | ||
500 mg | ¥ 5,930 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 686 | 现货 |
产品描述 | Astragaloside A (Astramembrannin I) (Astragaloside IV) is the primary pure saponin isolated from Astragalus membranaceus, which has been widely used for the therapy of cardiovascular diseases. |
体外活性 | Astragaloside IV improves post-ischemic heart function and ameliorated reperfusion arrhythmias accompanied by a significant increase in myocardial antioxidative enzyme superoxide dismutase activity in rat hearts in vitro. While, Astragaloside IV's protective effect on heart function can be partially abrogated by the nitric oxide synthase inhibitor, Nomega-nitro-L-arginine methyl ester. [1] |
体内活性 | Astragaloside IV significantly reduces infarct size in dogs subjected to coronary ligation in vivo. [1] Astragaloside IV attenuates isoproterenol-induced subendocardial necrosis, serum lactate dehydrogenase and creatine kinase activation, and lipid oxide product malondialdehyde formation in rats. It also reduces sarcoplasmic reticulum Ca(2+)-uptake ability and Ca(2+)-ATPase (SERCA2a) activity as well as SERCA2a mRNA expression in myocardial injury rats. [2] |
激酶实验 | In vitro PI3Kγ Kinase Assay: Human PI3Kγ (100 ng) is incubated at RT with kinase buffer (10 mM MgCl2, 1 mM β-glycerophosphate, 1 mM DTT, 0.1 mM Na3VO4, 0.1% Na Cholate and 15 M ATP/100 nCi γ[33]ATP, final concentrations) and lipid vesicles containing 18 M PtdIns and 250 M of PtdSer (final concentrations), in the presence of AS-252424 or DMSO. Kinase reaction is stopped by adding 250 g of Neomycin-coated Scintillation Proximity Assay (SPA) beads and preceded. |
别名 | Astragalin A, 黄芪甲苷, Astramembrannin I |
分子量 | 784.97 |
分子式 | C41H68O14 |
CAS No. | 83207-58-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 93 mg/mL (118.5 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.2739 mL | 6.3697 mL | 12.7393 mL | 31.8484 mL |
5 mM | 0.2548 mL | 1.2739 mL | 2.5479 mL | 6.3697 mL | |
10 mM | 0.1274 mL | 0.637 mL | 1.2739 mL | 3.1848 mL | |
20 mM | 0.0637 mL | 0.3185 mL | 0.637 mL | 1.5924 mL | |
50 mM | 0.0255 mL | 0.1274 mL | 0.2548 mL | 0.637 mL | |
100 mM | 0.0127 mL | 0.0637 mL | 0.1274 mL | 0.3185 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Astragaloside A 83207-58-3 Membrane transporter/Ion channel Metabolism Calcium Channel Astragalin A 黄芪甲苷 Astramembrannin I Inhibitor inhibitor inhibit